BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Total Share-Based Compensation Expense by Year
Total Share-Based Compensation Expense ($M) ($M)
BeOne Medicines Total Share-Based Compensation Expense: $510M in FY2025, up 15.5% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Share-Based Compensation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Share-Based Compensation Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 510 | +15.5% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 442 | +20.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 368 | +21.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 303 | +26.0% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 241 | +31.2% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 184 | +36.7% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 134 | +54.1% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 87.1 | +103.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 42.9 | +304.7% | Form 10-K (filed 2020-03-02) ↗ |
| FY2016 | Dec 31, 2016 | 10.6 | +3.9% | Form 10-K (filed 2019-02-28) ↗ |
| FY2015 | Dec 31, 2015 | 10.2 | – | Form 10-K (filed 2018-02-28) ↗ |
Breakdown
What makes up total Share-Based Compensation Expense
- Share-Based Compensation — Research & Development ($M)217 · FY2025
- Share-Based Compensation — Selling, General & Administrative ($M)293 · FY2025
- Share Options Outstanding at Year-End (M options)48.2 · FY2025
- Share Options Outstanding — Weighted-Average Exercise Price ($/sh)12.46 · FY2025
- Share Options Granted During Year (M options)2.53 · FY2025
- Share Options Granted — Weighted-Average Grant-Date Fair Value ($/sh)10.44 · FY2025
- Share Options Exercised During Year (M shares)30.1 · FY2025
- Total Intrinsic Value of Share Options Exercised ($M)449 · FY2025
- Share Options Forfeited / Cancelled During Year (M options)2.21 · FY2025
- Total Fair Value of Share Options Vested During Year ($M)56 · FY2025
Cite this data
StockData. (2026). BeOne Medicines Total Share-Based Compensation Expense ($M), annual FY2015–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/sbc-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.